FY2028 Earnings Forecast for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Equities research analysts at HC Wainwright raised their FY2028 earnings per share estimates for PolyPid in a research report issued on Wednesday, February 11th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $0.21 per share for the year, up from their prior forecast of $0.20. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s FY2030 earnings at $4.02 EPS.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07).

Several other equities research analysts have also recently issued reports on PYPD. Wall Street Zen upgraded shares of PolyPid from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a report on Monday, December 29th. Citigroup reiterated a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Finally, Roth Mkm dropped their target price on PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $12.25.

PolyPid Stock Down 0.6%

Shares of PYPD stock opened at $4.59 on Thursday. The company has a 50 day moving average price of $4.36 and a 200-day moving average price of $3.80. PolyPid has a 52 week low of $2.30 and a 52 week high of $5.12. The firm has a market capitalization of $72.98 million, a PE ratio of -2.03 and a beta of 1.52.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its stake in PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after acquiring an additional 3,500 shares during the period. HighTower Advisors LLC purchased a new stake in shares of PolyPid in the fourth quarter worth $44,000. Jane Street Group LLC purchased a new position in shares of PolyPid during the 4th quarter valued at $66,000. Lumbard & Kellner LLC bought a new position in PolyPid in the 2nd quarter worth $135,000. Finally, AIGH Capital Management LLC increased its stake in PolyPid by 27.0% in the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after buying an additional 253,727 shares in the last quarter. 26.47% of the stock is currently owned by institutional investors.

Key Headlines Impacting PolyPid

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” and modeled aggressive long-term upside (FY2028 EPS $0.21; FY2030 EPS $4.02) and set a $13 price target — signaling institutional conviction around D-PLEX₁₀₀ commercialization and large upside vs current levels. HC Wainwright research / MarketBeat
• Positive Sentiment: Company update: PolyPid says it is in advanced-stage U.S. partnership discussions for D-PLEX₁₀₀ — management and analysts flagged a “big 2026 catalyst” tied to commercialization progress, which could materially re-rate the stock if a partner deal or commercial plan is announced. GlobeNewswire press release
• Neutral Sentiment: Earnings call tone was mixed — management highlighted strategic and development advances for D-PLEX₁₀₀ but also discussed operational challenges and timing uncertainties around partnerships/launch, making near-term stock reaction dependent on concrete partnership milestones. TipRanks earnings call summary
• Negative Sentiment: Q4 results disappointed: EPS of -$0.41 missed the -$0.34 consensus. The company remains loss-making and consensus models a full-year EPS around -$1.79, keeping short-term valuation under pressure until revenue/partnership visibility improves. MarketBeat earnings report

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.